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INTRODUCTION
Cardiovascular disease (CVD) continues to be a substantial health-care burden despite recent treatment advances. Oxidative stress has long been regarded as a key pathophysiological mediator that ultimately leads to CVD including atherosclerosis, hypertension, and heart failure (Chen and Keaney, 2012) . Reactive oxygen species (ROS), which are involved in normal physiological functions at low concentrations, can have deleterious effects when produced in excess. Over time, ROS may result in a pathological state of imbalance known as oxidative stress. Most therapies that are currently being used may provide some reduction in oxidative stress, but there is no consensus on the clinical outcomes of various antioxidants. Currently, there are no antioxidant therapies that specifi cally target oxidative stress in patients with heart failure. Therefore, a better understanding of the mechanism of injury induced by oxidative stress related to CVD is needed (Ahmed and Tang, 2012) .
Previous studies have pointed out changes in the redox status of glutathione in a failing heart (Damy et al., 2009) . Glutathione (GSH) is a tripeptide (γ-glutamylcysteinyl glycine) that plays an important protective role against oxidative stressinduced damage in mammalian tissues (Sevin et al., 2013) .
Indeed, it acts as a substrate for scavenging ROS via the enzymes glutathione peroxidase and glutathione reductase. Reduction of cellular GSH, which allows ROS accumulation, has been shown to cause apoptosis in Jurkat T cells (van den Dobbelsteen et al., 1996) neutrophils (O'Neill et al., 2000) , and neural cells (Narasimhan et al., 2011) . Moreover, many studies have also examined the relationship between GSH levels and heart disease. Decreases in plasma GSH levels are associated with cardiomyocyte apoptosis (Kytö et al., 2004) and are correlated with the severity of heart failure symptoms in patients (Damy et al., 2009) . Hearts depleted of intrinsic GSH suffer from more functional damage infl icted by ischemia/reperfusion than do normal hearts (Blaustein et al., 1989) . Recently, it was reported that NOX4 induces GSH levels through regulation of Nrf2 in cardiomyocytes, and triggers the adaptive stress response to protect the heart (Brewer et al., 2011) . However, other studies have disputed these fi ndings, showing no signifi cant difference in functional integrity between GSHdepleted and GSH-adequate hearts (Chatham et al., 1988) . Therefore, whether or not oxidative stress induced by GSH depletion contributes to the progression of heart disease remains elusive.
Experimental depletion of cellular GSH can be produced by using L-buthionine-S,R-sulfoximine (BSO), a potent and spe-
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MATERIALS AND METHODS

Cell cultures and drug treatment
Heart-derived H9c2 cells were purchased from American Type Culture Collection (Rockville, MD, USA) and cultured in Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. H9c2 cells were pretreated with glutathione monoethyl ester (GME), protein kinase C (PKC)-ζ inhibitor (Santa Cruz Biotechnology, Santa Cruz, CA, USA), trolox, GF109203X, Go6976, or rottlerin (Sigma-Aldrich, St Louis, MO, USA) for 30 min. Subsequently, the cells were treated with 100 mM BSO (Sigma-Aldrich) in the presence or absence of GME or inhibitor.
Measurements of cellular GSH level
Intracellular GSH were measured using GSH colorimetric detection kit (BioVision, Milpitas, CA, USA). Briefl y, cells were lysed in GSH buffer for 10 min. Cell lysates centrifuged at 8,000 g for 10 min and supernatants were collected. Supernatants were incubated with reaction buffer for 10 min. After adding of substrate solution, GSH level were monitored at 405 nm using a microtiter plate reader (Molecular Devices, Sunnyvale, CA, USA).
Measurements of ROS release
Intracellular ROS were measured fl uorometrically using 2',7'-dichlorofl uorescein (DCF) diacetate (DA) (Molecular probes, Eugene, OR, USA), which permeates cells easily and hydrolyzes to DCF after interacting with intracellular ROS. Cultured cells were washed twice with HCSS incubated with 10 μM DCF-DA and 20% Pluronic F-127 for 30 min, and washed with HCSS, as described previously . Subsequently, cells were observed under a confocal microscope (Olympus, Tokyo, Japan). DCF fl uorescence intensities were obtained in Fluoview FV300 software. DCF sample values are expressed as percentage relative to the control value.
Flow cytometric analysis for propidium iodide (PI)/annexin V staining
Apoptotic and necrotic cells were detected by double staining with PI and annexin V-FITC using the annexin-V apoptosis detection kit I (BD PharMingen, San Diego, CA, USA) Yang et al., 2012) . Briefl y, cells were detached by trypsin-EDTA treatment, gently resuspended in cold binding buffer to 5×10 5 cells, and incubated with annexin V-FITC and PI at room temperature in the dark. Living cells were defi ned as those negatively stained for both PI and annexin V. Early apoptotic cells were defi ned as those staining positive for annexin V and negative for PI. Late apoptotic cells were defi ned as those staining positively for both. Necrotic cells were defi ned as those staining only with PI. The fl uorescence intensity of the cell surface was measured by fl ow cytometry (FACSVantage, Becton Dickinson, Franklin Lakes, NJ, USA). Values are expressed as the percentage of annexin V-positive cells to total cells counted.
Nuclei staining
Cells were fi xed with 4% paraformaldehyde for 10 min. Cell were incubated with Hoechst 33258 for 10 min. All samples were then observed under a confocal microscope (Olympus, Tokyo, Japan).
Measurement of caspase-3 activity
Cells were washed once with ice-cold phosphate-buffered saline and extracted on ice in lysis buffer (10 mM Tris-HCl, 0.32 M sucrose, 10 mM DTT, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 μg/ml aprotinin, and 10 μM leupeptin) for 1 h. Lysates were centrifuged at 10,000 g for 10 min at 4 o C, and 200 μg of cytosolic extracts were mixed with reaction buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 10 mM DTT, and 10 μM leupeptin) to a fi nal volume of 100 μl containing 200 μM of Ac-DEVD-p-Na. Samples were then incubated for 2 h at 37 o C, as described previously . The enzyme-catalyzed release of p-nitroanilide was monitored at 405 nm using a microtiter plate reader (Molecular Devices, Sunnyvale, CA, USA). 
Lactate dehydrogenase (LDH) assay
Cell death was analyzed by measuring LDH release into medium as described previously . Briefl y, 24 h after BSO treatment, 25 μl medium was collected from each well and mixed with 100 μl NADH solution (0.03% β-NAD [reduced form of the disodium salt] in phosphate buffer) and 25 μl pyruvate solution (22.7 mM pyruvic acid in phosphate buffer) at room temperature. NADH consumption was followed for 2 min at 340 nm. The percent LDH was calculated from the maximum LDH release (100%) induced by lysing cells with 0.1% Triton X-100.
Western blot
Protein expression of PKC-δ was measured using western blot analysis as previously described . Cells were lysed using lysis buffer (50 mmol/L Tris-HCl, pH 7.4, 1% NP-40, 150 mmol/L NaCl, 0.25% Na-deoxycholate, 2 mmol/L EDTA, 1 mmol/L NaF, 1 mmol/L Na 3 VO 4 , 1 mmol/L PMSF, 10 μg/ml of aprotinin, and 10 μmol/L leupeptin). Lysates were subsequently centrifuged at 14,000 rpm for 15 min and supernatants were collected. Then, equal amounts of protein were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and reacted with anti-PKC-δ antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-β-actin antibody (Sigma-Aldrich). After probing with horseradish peroxidase (HRP)-conjugated secondary antibody, proteins were visualized using LAS 1000 (Fuji Photo Film, Tokyo, Japan).
Statistical analysis
All data are expressed as mean ± S.E.M. Numerical data were compared using the Student's t-test for paired observations between two groups. A p value<0.05 was considered signifi cant.
RESULTS
Depletion of GSH induced ROS generation
To determine the effect of GSH depletion on BSO-induced ROS generation, we used GME to maintain the intracellular GSH concentration in the presence of BSO (Torres et al., 1997) . The GSH level in H9c2 cells decreased by treatment with 10 mM BSO and was approximately 80% at 0.5 h, 57% at 1 h, 46% at 4 h, and 43% at 12 h after treatment (Fig. 1A) . The decrease in cellular GSH levels by BSO was restored to control levels by GME (300 μM). However, trolox (10 μM), an ROS scavenger, had no infl uence on the cellular GSH level. 
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As shown in Fig. 1B , ROS production was signifi cantly increased by BSO. BSO-induced ROS generation was dramatically decreased by GME or trolox at each time point. These results suggest that BSO induced ROS generation through the depletion of cellular GSH levels.
Depletion of GSH induced cell death of cardiomyocytes
We examined the effect of GME on BSO-induced cell death. BSO remarkably increased annexinV-positive cells to 19.8% at 12 h, 27.5% at 14 h, and 26.8% at 18 h, indicating that BSO induce apoptosis of H9c2 cells (Fig. 2A) . The BSOinduced apoptosis was blocked by treatment with GME (5.3% at 12 h, 9.3% at 14 h, and 6.9% at 18 h). BSO also increased annexinV-negative/PI-positive cells to 20.3% at 14 h, 28.7% at 18 h, and 34.7% at 22 h, indicating induction of necrosis of H9c2 cells (Fig. 2B) . Treatment with GME inhibited the BSOinduced necrosis (10% at 14 h, 13.3% at 18 h, and 17.6%). Treatment with trolox blocked only BSO-induced apoptosis but not BSO-induced necrosis. Consistently, BSO increased the frequency of apoptotic cells with fragmented nuclei and condensed chromatin compared with control cells (Fig. 2C) . Treatment with GME completely protected cells from morphological changes by BSO. Next, we examined the effect of GME on the activation of caspase-3, which plays an important role in apoptotic cell death. As shown in Fig. 2D , caspase-3 activity was signifi cantly increased to 250% at 14 h, and reached its maximal level (350%) at 16 h after BSO treatment. This BSOinduced caspase-3 activity was dramatically inhibited by GME or trolox. These results suggest that BSO induced apoptosis and necrosis through the depletion of cellular GSH levels.
PKC-δ contributed to BSO-induced cell death and ROS production
We further examined the effect of PKC isotypes on BSOinduced cell death. As shown in Fig. 3A , LDH release was remarkably increased by BSO compared to that observed in the control condition. This BSO-induced LDH release (61%) was decreased by the general PKC inhibitor (GF109203X, 18%) or the PKC-δ inhibitor (rottlerin, 15%). However, the conventional PKC inhibitor (Go6983) or the PKC-ζ inhibitor did not inhibit BSO-induced LDH release. Next, we determined the effect of various PKC inhibitors on ROS production (Fig. 3B) . Consistent with LDH release, BSO-induced ROS generation (189%) was blocked by the GF109203X (103%) and the rottlerin (112%). These results suggest that PKC-δ plays a role in BSO-induced ROS production and cell death.
Depletion of GSH induced activation of PKC-δ
We determined the effect of GME on BSO-induced activation of PKC-δ. As shown in Fig. 4A , PKC-δ began to translocate to the membrane fraction from the cytosol fraction at 1 h after BSO treatment. Treatment with GME inhibited this BSO-induced translocation of PKC-δ (Fig. 4B) . These results suggest that depletion of cellular GSH levels mediates BSOinduced PKC-δ activation. 
DISCUSSION
In the present study, using a heart-derived H9c2 cell line, we observed that BSO-induced GSH depletion was associated with: 1) increased apoptosis, 2) increased ROS production, 3) increased caspase-3 activity, and 4) increased PKC-δ activity. These results support our hypothesis that BSO-induced GSH depletion induces cardiomyocyte apoptosis through PKC-δ activation.
In patients with chronic heart failure, it is reported that increased oxidative stress is associated with reduced left ventricular function and is correlated with the severity of the disease (Belch et al., 1991; Mallat et al., 1998; Maack et al., 2003) . Furthermore, cell culture and animal studies have suggested that ROS may be important mediators of cardiac hypertrophy and the development of contractile dysfunction (Dhalla et al., 2000; Maack et al., 2003) . Ischemia results in impaired antioxidant defense, and subsequent reperfusion results in an increased concentration of ROS (Molyneux et al., 2002) . Depletion of cellular antioxidants such as GSH allows for the generation of signifi cant quantities of ROS, which have been suggested to act as signals for the induction of apoptosis (Armstrong et al., 2002) . Many models have been proposed to explain the induction of GSH depletion. Depletion of GSH may be induced by GSH synthesis inhibitors (e.g., BSO), GSH-S-transferase-dependent thiol alkylation agents (e.g., diethyl maleate, phorone, etc.), peroxides (e.g., tert-butyl hydroperoxide, H 2 O 2 , etc.), and non-enzymatic GSH-reacting agents (e.g., diazene and diamide). We chose to use the GSH synthesis inhibitor BSO because of its specifi city and because the block in GSH synthesis can be overcome by supplying the cell with GME (Torres et al., 1997) .
Results of previous studies showed that BSO-induced GSH depletion caused the induction of apoptotic and necrotic cell death in a variety of cell types (Rees et al., 1995; Korystov et al., 1996) . In cardiomyocytes, mitochondrial GSH depletion was shown to modulate apoptosis in short-term diabetic rat hearts (Ghosh et al., 2005) . However, the mechanism by which the depletion of GSH modulates cell death is still unclear. Our results showed that the BSO-induced depletion of cellular GSH levels signifi cantly increased ROS generation and apoptotic cell death in H9c2 cells (Fig. 1, 2) . Apoptosis is generally associated with the activation of caspase cascades (Logue and Martin, 2008) and with the Bcl-2 protein family (Gross et al., 1999) . In addition, apoptosis is accompanied by signs of mitochondrial dysfunction, including the loss of mitochondrial membrane potential and the release of cytochrome c (Gottlieb et al., 2003) . One of the main consequences following mitochondrial cytochrome c release is the activation of caspase-3. Caspase-3 is an effector caspase with a wide spectrum of substrates, and plays a critical role in characteristic apoptotic changes (Chang and Yang, 2000) . Our results showed that caspase-3 activity increased under conditions of BSO-induced GSH depletion (Fig. 2D) . Thus, we clearly demonstrated that BSO-induced GSH depletion signifi cantly increases apoptosis by the mitochondrial pathway through ROS generation.
It has been demonstrated that PKCs are one of the most important mediators of ischemia-induced changes. The PKC family is comprised of several serine/threonine protein kinases, and has been implicated as an intracellular mediator that is important in the regulation of growth, differentiation, cell death, and neurotransmission. The PKC subfamilies include conventional PKC (PKC-α, -β1, -β2, and -γ), novel PKC (PKC-δ, -ε, -η, -θ, and -ι), and atypical PKC (PKC-ζ, -μ, and -λ). Different isoforms may perform distinct functions, as suggested by their differential pattern of localization, differences in their activation conditions, and some differences in substrate specifi city. PKC-α, -β, -δ, -ε, and -ζ subtypes are known to be predominant isoforms in the rat heart (Doble et al., 2000; Kim et al., 2004) . In previous study, we reported that the role of PKC-δ under hypoxia-induced apoptosis (Kim et al., 2004) . In rat cardiomyocytes, it is also addressed the role of PKC-δ in cellular redox balance and apoptosis in various experimental conditions. Indeed, PKC-δ was cleaved by caspase-3 under doxorubicin-induced oxidative stress (Lai et al., 2011) and PKC-δ regulated apoptosis by H2O2-induced oxidative stress (Cieslak and Lazou, 2007) . However, its role in GSH depletion-induced cardipmyocyte apoptosis has not been elucidated. Our results showed that PKC-δ was activated by the BSO-induced depletion of cellular GSH, and rottlerin, a PKC-δ inhibitor, signifi cantly inhibited BSO-induced ROS production and cell death (Fig. 3, 4) . This indicates that PKC-δ regulates the ROS generation and cell death induced by GSH depletion.
In summary, our results showed that BSO-induced depletion of cellular GSH induces the translocation of PKC-δ and, subsequently, the generation of ROS, which appears to enhance H9c2 cell death. 
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